Earnings Feed
Start Free
Home/Filings/4/0001470831-26-000026
4//SEC Filing

Kumar Neil 4

Accession 0001470831-26-000026

CIK 0001743881other
View on SEC.govCompany Profile

Filed

Jan 11, 7:00 PM ET

Accepted

Jan 12, 9:01 PM ET

Size

33.0 KB

Accession

0001470831-26-000026

Insider Transaction Report

Form 4
Period: 2026-01-08
BridgeBio Pharma, Inc.BBIO
Kumar Neil
DirectorChief Executive Officer
Transactions
  • Sale

    Common Stock

    [F1][F2][F3]
    2026-01-08$73.64/sh−11,515$848,018→ 744,171 total(indirect: By Trust)
  • Sale

    Common Stock

    [F1][F4][F3]
    2026-01-08$74.38/sh−8,085$601,340→ 736,086 total(indirect: By Trust)
  • Sale

    Common Stock

    [F1][F5][F3]
    2026-01-08$75.16/sh−400$30,064→ 735,686 total(indirect: By Trust)
  • Sale

    Common Stock

    [F1][F6][F3]
    2026-01-08$73.65/sh−11,565$851,811→ 4,546,882 total(indirect: By Trust)
  • Sale

    Common Stock

    [F1][F7][F3]
    2026-01-08$74.38/sh−8,135$605,061→ 4,538,747 total(indirect: By Trust)
  • Sale

    Common Stock

    [F1][F5][F3]
    2026-01-08$75.20/sh−300$22,561→ 4,538,447 total(indirect: By Trust)
  • Sale

    Common Stock

    [F1][F8][F3]
    2026-01-09$75.75/sh−2,151$162,943→ 733,535 total(indirect: By Trust)
  • Sale

    Common Stock

    [F1][F9][F3]
    2026-01-09$76.72/sh−6,955$533,569→ 726,580 total(indirect: By Trust)
  • Sale

    Common Stock

    [F1][F10][F3]
    2026-01-09$77.61/sh−10,519$816,365→ 716,061 total(indirect: By Trust)
  • Sale

    Common Stock

    [F1][F11][F3]
    2026-01-09$78.19/sh−375$29,322→ 715,686 total(indirect: By Trust)
  • Sale

    Common Stock

    [F1][F12][F3]
    2026-01-09$75.61/sh−1,401$105,928→ 4,537,046 total(indirect: By Trust)
  • Sale

    Common Stock

    [F1][F13][F3]
    2026-01-09$76.53/sh−6,067$464,289→ 4,530,979 total(indirect: By Trust)
  • Sale

    Common Stock

    [F1][F14][F3]
    2026-01-09$77.46/sh−10,677$827,016→ 4,520,302 total(indirect: By Trust)
  • Sale

    Common Stock

    [F1][F15][F3]
    2026-01-09$78.10/sh−1,855$144,882→ 4,518,447 total(indirect: By Trust)
Holdings

  • Common Stock

    228,776
Footnotes (15)
  • [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
  • [F10]Represents the weighted average sale price of the shares sold from $77.16 to $78.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F11]Represents the weighted average sale price of the shares sold from $78.16 to $78.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F12]Represents the weighted average sale price of the shares sold from $74.99 to $75.97 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F13]Represents the weighted average sale price of the shares sold from $75.99 to $76.985 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F14]Represents the weighted average sale price of the shares sold from $76.99 to $77.96 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F15]Represents the weighted average sale price of the shares sold from $78.00 to $78.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F2]Represents the weighted average sale price of the shares sold from $73.05 to $74.03 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F3]The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
  • [F4]Represents the weighted average sale price of the shares sold from $74.06 to $74.94 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F5]Represents the weighted average sale price of the shares sold from $75.09 to $75.28 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F6]Represents the weighted average sale price of the shares sold from $73.08 to $74.06 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F7]Represents the weighted average sale price of the shares sold from $74.08 to $75.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F8]Represents the weighted average sale price of the shares sold from $75.12 to $76.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F9]Represents the weighted average sale price of the shares sold from $76.13 to $77.125 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Signature
/s/ Will Solis, Attorney-in-Fact|2026-01-12

Documents

1 file

Issuer

BridgeBio Pharma, Inc.

CIK 0001743881

→
Entity typeother

Related Parties

1
  • filerCIK 0001742485

Filing Metadata

Form type
4
Filed
Jan 11, 7:00 PM ET
Accepted
Jan 12, 9:01 PM ET
Size
33.0 KB
View on SEC.gov